BVF INC/IL
SEC CIK 1056807 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | Dir, See Explanation of Responses | 370.7K | — | — | 1 | 2024-12-04 | 2024-12-04 |
| ELDN | Eledon Pharmaceuticals, Inc. | 10% | 220.5K | — | — | 1 | 2024-05-09 | 2024-05-09 |
| CGEM | Cullinan Therapeutics, Inc. | 10% | 3.60M | $10.06M | — | 1 | 2022-05-12 | 2022-05-12 |
| KYMR | Kymera Therapeutics, Inc. | See Explanation of Responses | 2.03M | $9.94M | — | 2 | 2022-01-27 | 2022-05-05 |
Most active insiders at OLMA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | CLARK IAN T | Dir | — | $7.87M |
| 2 | Zojwalla Naseem | Chief Medical Off | — | $7.53M |
| 3 | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | — | $4.66M |
| 4 | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | — | $2.98M |
| 5 | Mitchell Shawnte | CLO | — | $951.5K |
| 6 | Harmon Cyrus | Dir | — | $743.8K |
| 7 | Austin Sasha Lu | VP of Fin, Ctrl | — | — |
| 8 | Bohen Sean | Pres, CEO, Dir | — | — |
| 9 | RAPPAPORT ANDREW | Dir | — | — |
BVF INC/IL made no open-market trades at OLMA in the last 12 months.
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-04 | 2024-12-04 | OLMA | Olema Pharmaceuticals, Inc. | BVF INC/IL | Dir, See Explanation of Responses | D - Sale to Iss | — | -3.37M | 370.7K | -90% | — |
| DM | 2024-05-13 | 2024-05-09 | ELDN | Eledon Pharmaceuticals, Inc. | BVF INC/IL | 10% | P - Purchase | — | +1.93M | 220.5K | New | — |
| M | 2022-05-16 | 2022-05-12+ | CGEM | Cullinan Therapeutics, Inc. | BVF INC/IL | 10% | P - Purchase | $9.07 | +1.11M | 3.60M | +45% | +$10.06M |
| M | 2022-05-09 | 2022-05-05+ | KYMR | Kymera Therapeutics, Inc. | BVF INC/IL | Dir, See Remarks, Footnotes | P - Purchase | $19.46 | +250.0K | 2.03M | +14% | +$4.87M |
| M | 2022-01-31 | 2022-01-27+ | KYMR | Kymera Therapeutics, Inc. | BVF INC/IL | See Explanation of Responses | P - Purchase | $38.96 | +130.3K | 1.88M | +7% | +$5.08M |
Purchase Sale Sale after option exercise All abbreviations